List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 88 studies with search of: Open Studies | "Breast Neoplasms, Male"
Include studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Recruiting Study of Patients With Male Breast Cancer Treated Within the Past 20 Years
Condition: Breast Cancer
Interventions: Other: laboratory biomarker analysis;   Other: medical chart review;   Procedure: study of high risk factors
2 Not yet recruiting Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Drug: cyclophosphamide;   Biological: ex vivo-expanded HER2-specific T cells;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Other: immunoenzyme technique
3 Recruiting Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: mifepristone;   Drug: placebo;   Drug: nab-paclitaxel
4 Recruiting Pazopanib Hydrochloride and Anastrozole Before Surgery in Treating Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer
Interventions: Drug: anastrozole;   Drug: pazopanib hydrochloride;   Procedure: therapeutic conventional surgery
5 Not yet recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Primary Hepatocellular Carcinoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Hormone-resistant Prostate Cancer;   Limited Stage Small Cell Lung Cancer;   Localized Resectable Adult Primary Liver Cancer;   Male Breast Cancer;   Mast Cell Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Gastric Cancer;   Recurrent Kaposi Sarcoma;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Osteosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage IA Breast Cancer;   Stage IA Gastric Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Breast Cancer;   Stage IB Gastric Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Breast Cancer;   Stage II Uterine Sarcoma;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIB Melanoma;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Melanoma;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Melanoma;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IV Bladder Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sirolimus;   Other: laboratory biomarker analysis;   Biological: DEC-205-NY-ESO-1 fusion protein vaccine
6 Recruiting Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Procedure: leukapheresis;   Biological: ex vivo-expanded HER2-specific T cells;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Biological: sargramostim;   Other: flow cytometry;   Other: immunoenzyme technique;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction
7 Recruiting Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: vorinostat;   Drug: ixabepilone;   Other: laboratory biomarker analysis;   Other: pharmacological study
8 Recruiting Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Hereditary Breast/Ovarian Cancer - BRCA1;   Hereditary Breast/Ovarian Cancer - BRCA2;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Other: immunohistochemistry staining method;   Genetic: gene expression analysis;   Drug: veliparib;   Drug: cisplatin;   Drug: vinorelbine tartrate;   Other: pharmacological study;   Other: laboratory biomarker analysis
9 Recruiting Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
Conditions: HER2-negative Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: paclitaxel;   Biological: bavituximab;   Other: laboratory biomarker analysis;   Other: pharmacological study
10 Recruiting Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Skin Metastases;   Stage IV Breast Cancer
Interventions: Drug: imiquimod;   Drug: Abraxane;   Other: laboratory biomarker analysis;   Genetic: RNA analysis;   Other: immunoenzyme technique
11 Recruiting Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: vorinostat;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Radiation: F-18 16 alpha-fluoroestradiol;   Procedure: positron emission tomography;   Drug: anastrozole;   Drug: letrozole;   Drug: exemestane;   Genetic: gene expression analysis
12 Not yet recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: questionnaire administration
13 Recruiting Endoscopic Breast Surgery in Treating Patients With Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Procedure: endoscopic surgery;   Procedure: quality-of-life assessment
14 Not yet recruiting Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: eribulin mesylate;   Drug: carboplatin;   Procedure: biopsy
15 Recruiting PD 0332991 in Treating Patients With Refractory Solid Tumors
Conditions: Adult Solid Tumor;   Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Adult Central Nervous System Germ Cell Tumor;   Adult Teratoma;   Benign Teratoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Familial Testicular Germ Cell Tumor;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Male Breast Cancer;   Ovarian Immature Teratoma;   Ovarian Mature Teratoma;   Ovarian Monodermal and Highly Specialized Teratoma;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Extragonadal Germ Cell Tumor;   Recurrent Extragonadal Non-seminomatous Germ Cell Tumor;   Recurrent Extragonadal Seminoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Melanoma;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Rectal Cancer;   Stage III Extragonadal Non-seminomatous Germ Cell Tumor;   Stage III Extragonadal Seminoma;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Ovarian Germ Cell Tumor;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Extragonadal Non-seminomatous Germ Cell Tumor;   Stage IV Extragonadal Seminoma;   Stage IV Melanoma;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Rectal Cancer;   Testicular Immature Teratoma;   Testicular Mature Teratoma
Interventions: Drug: PD-0332991;   Other: pharmacological study
16 Recruiting Vaccine Therapy in Combination With Ampligen® and/or Sargramostim in Patients With Stage II-IV HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Ampligen;   Biological: synthetic HER-2/neu peptide vaccine;   Biological: GM-CSF;   Other: laboratory biomarker analysis;   Other: immunoenzyme technique
17 Recruiting Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
Conditions: Inflammatory Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: sunitinib malate;   Drug: paclitaxel;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: filgrastim;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Other: flow cytometry
18 Recruiting Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: palliative surgery;   Procedure: therapeutic conventional surgery;   Radiation: palliative radiation therapy;   Radiation: radiation therapy
19 Recruiting DNA Analysis of Tumor Tissue Samples From Patients With Recurrent or Metastatic Breast Cancer That Expresses HER2
Condition: Breast Cancer
Interventions: Genetic: comparative genomic hybridization;   Genetic: fluorescence in situ hybridization;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Procedure: histopathologic examination
20 Recruiting Entinostat and Lapatinib Ditosylate in Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab
Condition: Breast Cancer
Interventions: Drug: entinostat;   Drug: lapatinib ditosylate;   Genetic: protein expression analysis;   Other: circulating tumor cell analysis;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40)
† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services